Market Trends of Tetanus Toxoid Vaccine Industry
The Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment is Expected to Hold a Significant Market Share in the Tetanus Toxoid Vaccine Market Over the Forecast Period
Diphtheria, tetanus, and pertussis (DTaP) vaccine segment are anticipated to witness growth in the tetanus toxoid vaccine market owing to factors such as growing government initiatives to eradicate these diseases, a rise in product launches and an increase in pipeline studies for the development of DTaP vaccines. DTaP is a vaccine that helps in developing immunity against three deadly diseases, diphtheria, tetanus, and whooping cough (pertussis), in children younger than seven years old. According to a vaccine-preventable disease update by the WHO in 2022, a total number of 144 cases of diphtheria were reported by seven countries (Austria, France, Germany, Italy, Norway, Switzerland, and the United Kingdom), many of which were among asylum seekers. Of the 144 cases, 97 (69%) were classified as clinically compatible, 44 (31%) were laboratory confirmed as toxigenic diphtheria cases, and 3 (2%) were suspected cases.
Moreover, as per a July 2022 update from the WHO, in 2021, about 81% of infants worldwide (105 million infants) received 3 doses of the diphtheria-tetanus-pertussis (DTP3) vaccine, protecting them against infectious diseases that can cause serious illness and disability or be fatal. Furthermore, as per the 2022 Provisional Pertussis Surveillance Report published by CDC, 2,388 cases of pertussis were reported in the United States in 2022, up from 1,609 cases in 2021. Hence, an increase in pertussis cases is likely to demand the availability of vaccines and thereby driving the segment growth.
Additionally, collaborations by key players to launch the DTap vaccines in different countries boost the market growth. For instance, in June 2021, Merck & Co. Inc. and Sanofi collaborated to launch VAXELIS (diphtheria and tetanus toxoids vaccine) in the United States.
North America is Expected to Hold a Significant Share in the Market during the Forecast Period
North America is expected to hold a significant market share in the tetanus toxoid vaccine market due to the increase in increasing government initiatives programs for vaccination, the surge in diphtheria, pertussis, and tetanus cases, and the rise in research initiatives for the development of vaccines. According to a November 2022 update from the Department of Minnesota, 22 cases of pertussis were reported in the Minnesota region till November 2022. Furthermore, as per the Florida Health Report, in 2022, 47 pertussis cases were reported in 18 counties. There was a 45% increase in the number of pertussis cases reported between May 2022 to October 2022 compared to May 2021 to October 2021 (n=22 cases).
Furthermore, the rise in government initiatives for vaccinations against tetanus and diphtheria boost the market growth over the forecast period. For instance, in April 2022, Ontario expanded its publicly funded Tdap immunization program to include a routine dose in every pregnancy for protection against pertussis, regardless of previous Tdap immunization history. Canada's National Advisory Committee on Immunization recommended that all pregnant individuals get the pertussis (whooping cough) vaccine during every pregnancy to help protect the baby after birth.
